Cardio Diagnostics, specializing in AI-driven DNA biomarker testing for cardiovascular disease, reported a net loss of $6.9M and an accumulated deficit of $21.2M as of September 30, 2024. The company is addressing going concern uncertainty due to limited revenue and accumulated losses.To mitigate financial challenges, Cardio Diagnostics raised $1M through a private placement in February 2024 and $4.2M via an at-the-market stock offering in 2024, with an additional $2.6M raised post-September 30, 2024. The company terminated an $11.2M convertible debenture agreement with Yorkville on January 4, 2024.Cardio Diagnostics received a Nasdaq non-compliance notice on June 3, 2024, for a bid price below $1.00, with a deadline to regain compliance by December 2, 2024, potentially extending to May 29, 2025.

Cardio Diagnostics, specializing in AI-driven DNA biomarker testing for cardiovascular disease, reported a net loss of $6.9M and an accumulated deficit of $21.2M as of September 30, 2024. The company is addressing going concern uncertainty due to limited revenue and accumulated losses.To mitigate financial challenges, Cardio Diagnostics raised $1M through a private placement in February 2024 and $4.2M via an at-the-market stock offering in 2024, with an additional $2.6M raised post-September 30, 2024. The company terminated an $11.2M convertible debenture agreement with Yorkville on January 4, 2024.Cardio Diagnostics received a Nasdaq non-compliance notice on June 3, 2024, for a bid price below $1.00, with a deadline to regain compliance by December 2, 2024, potentially extending to May 29, 2025.